SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

June 11, 2010 08:45 ET

Radient Pharmaceuticals Announces New Interactive Website Dedicated to Company's Onko-Sure™ In Vitro Diagnostic Cancer Test

TUSTIN, CA--(Marketwire - June 11, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today launched a new interactive website for its USFDA-approved Onko-Sure™ in vitro diagnostic (IVD) cancer test. The site, which can be found at, offers detailed information on RPC's proprietary, USFDA-approved Onko-Sure IVD cancer test, CLIA laboratory testing resources and general information on cancer screening, testing and treatment. 

"This online tool and resource is designed to help educate people on RPC's Onko-Sure IVD cancer test and its merits as a non-invasive, simple blood test for cancer testing," said Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "Our goal is to provide a single place where people seeking information about Onko-Sure can easily find what they need. The site is fully dedicated to Onko-Sure and serves as an extension to the corporate Radient Pharmaceuticals website. We plan to update the site regularly to ensure we're providing the most useful and current information to physicians, clinicians and patients."

Information about RPC's Onko-Sure IVD cancer test forms the core of the site, including product facts, scientific literature and basic information about cancer and cancer testing. Visitors will also find a useful FAQ section with answers to the most commonly asked questions about Onko-Sure. Radient Pharmaceuticals will continue to build the site to include product development news and information and international language translations for global markets where Onko-Sure is available.

RPC's Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products. Visit for additional information.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323